Sign in

You're signed outSign in or to get full access.

CL

Comera Life Sciences Holdings, Inc. (CMRA)·Q3 2023 Earnings Summary

Executive Summary

  • Q3 revenue declined sequentially to $0.14M as Regeneron collaboration hours tapered in the final stage of technical evaluation; net loss was $2.15M (−$0.10 EPS). Management reiterated the Regeneron evaluation should complete in Q4 2023, a near‑term catalyst for potential licensing talks .
  • Operating discipline continued: G&A fell year over year to $1.89M (from $2.31M) and R&D to $0.37M (from $0.39M), driving a narrower YoY loss and EPS improvement (−$0.10 vs −$0.20) despite lower revenue .
  • Liquidity improved from Q2: cash and cash equivalents rose to $1.77M (from $0.48M) aided by the previously announced $4.1M private placement completed during Q3; current liabilities also fell to $2.93M (from $3.95M) .
  • Strategic progress: expanded IP estate (multiple new patents/notices), manufacturing partnership for a lead excipient, and European patent notice, supporting the SQore platform’s commercialization readiness .
  • Wall Street consensus (S&P Global) was unavailable for CMRA this quarter; estimate comparisons cannot be provided. Values could not be retrieved due to missing mapping in S&P Global systems.

What Went Well and What Went Wrong

What Went Well

  • Platform/IP momentum: “Expanded and strengthened Comera’s global patent portfolio… broaden[ing] both geographic coverage and claims for core SQore excipient technology.” Management also received a European patent intention to grant and highlighted peer‑reviewed data supporting SQore excipients .
  • Partnership progress: “Final stage of technical evaluation is near completion” with Regeneron; evaluation expected to complete in Q4 2023, unlocking a right to negotiate a license .
  • Balance sheet actions: Completed the $4.1M private placement in two closings, strengthening liquidity; subsequent financing triggered a preferred redemption mechanism under the certificate of designation and signaled ongoing capital access .

What Went Wrong

  • Revenue compression: Q3 revenue fell to $0.14M from $0.32M in Q2 and $0.23M in Q3’22 as collaboration hours declined late in the evaluation phase, limiting top‑line leverage .
  • Scale vs. cost base: Even with YoY OpEx declines, limited revenue scale kept losses elevated (Q3 net loss $2.15M), and gross margin variability reflected small denominator effects (gross margin ~69%) .
  • Listing/compliance overhang: While Nasdaq granted continued listing in Q2 subject to conditions, the company still needed to execute milestones to ensure compliance, sustaining a governance/liquidity narrative risk through Q3 .

Financial Results

Income statement – last three quarters (USD)

MetricQ1 2023Q2 2023Q3 2023
Revenue ($)$393,000 $315,055 $136,310
Cost of Revenue ($)$117,000 $56,040 $41,961
Gross Profit ($)$276,000 (calc) $259,015 (calc) $94,349 (calc)
Gross Margin (%)70.2% (calc) 82.2% (calc) 69.2% (calc)
R&D Expense ($)$344,000 $235,696 $366,015
G&A Expense ($)$2,400,000 $1,503,553 $1,885,405
Net Loss ($)$2,600,000 $1,411,620 $2,153,711
Diluted EPS ($)−$0.13 −$0.08 −$0.10

YoY snapshot – Q3 (USD)

MetricQ3 2022Q3 2023
Revenue ($)$234,922 $136,310
Cost of Revenue ($)$60,963 $41,961
R&D Expense ($)$394,800 $366,015
G&A Expense ($)$2,314,554 $1,885,405
Net Loss ($)$3,076,841 $2,153,711
Diluted EPS ($)−$0.20 −$0.10

Liquidity and capital (period-end)

MetricQ2 2023Q3 2023
Cash & Cash Equivalents ($)$476,302 $1,767,870
Restricted Cash – Current ($)$1,505,625 —
Restricted Cash – Non‑Current ($)$50,000 $50,000
Total Current Assets ($)$1,824,034 $2,630,496
Total Current Liabilities ($)$3,953,545 $2,932,419
Stockholders’ Deficit ($)$(6,350,362) $(4,220,602)

Notes:

  • Q1 2023 liquidity disclosed as $1.6M cash, cash equivalents and restricted cash (press release); not directly comparable to the “cash & equivalents” line above .

Segments/KPIs

  • No reportable segments; revenue is primarily collaboration‑related (e.g., Regeneron) .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Financial guidanceFY/Q3 2023NoneNoneMaintained (no formal guidance provided)

Earnings Call Themes & Trends

Note: No Q3 2023 earnings call transcript was available in the document set; themes below are synthesized from quarterly press releases.

TopicPrevious Mentions (Q1 & Q2 2023)Current Period (Q3 2023)Trend
Regeneron collaboration“Significant progress… right to negotiate a license after technical evaluation” (Q1) ; “Advanced to final stage of technical evaluation” (Q2) “Final stage… near completion; evaluation expected in Q4 2023” with licensing negotiation right Approaching potential licensing inflection
IP/patent estateAdded S. Korea patent and US/Japan NOAs (Q1) ; four new patents + two NOAs across US/Canada/Korea/India (Q2) Additional portfolio expansion; European patent notice to grant Strengthening protection breadth
Financing/listingPrivate placement agreement signed; Nasdaq granted continued listing subject to conditions (Q2) $4.1M private placement completed in two closings; preferred redemption mechanics noted Liquidity shored up; compliance actions ongoing
Manufacturing/supply chainQuality Chemical collaboration announced to manufacture lead excipient (Q2) Partnership reiterated; emphasis on GMP supply chain control Building CMC readiness
Proprietary programsCLS‑001 lead formulation identified for once‑monthly SQ vedolizumab (Q1) Focused on enabling SQ delivery via SQore across programs Platform‑led development roadmap

Management Commentary

  • “Comera continues to generate significant momentum, by expanding our patent portfolio, strengthening our cash position and advancing key partnerships… we remain focused on our mission to improve patient quality of life… leveraging our SQore platform to transform the delivery of biologics from intravenous to self‑administered subcutaneous forms.” — Jeffrey Hackman, Chairman & CEO .
  • Q2 tone emphasized operational and financing progress: “We made substantial progress… advancing our ongoing collaboration with Regeneron, bolstering our intellectual property… and strengthening our cash position.” — Jeffrey Hackman .
  • Q1 highlighted pipeline traction: “Significant advancement… including our collaboration with Regeneron, and sustained progression of… CLS‑001, a subcutaneous formulation of vedolizumab.” — Jeffrey Hackman .

Q&A Highlights

  • An earnings call transcript for Q3 2023 was not found in the available materials; therefore, Q&A themes and management clarifications are not available from a transcript this quarter.

Estimates Context

  • S&P Global consensus estimates for CMRA (revenue/EPS) for Q3 2023 were unavailable due to missing mapping in S&P Global systems at query time; as a result, no estimate comparisons can be provided this quarter. Values retrieved from S&P Global were unavailable.

Key Takeaways for Investors

  • Near‑term catalyst: Regeneron technical evaluation slated to complete in Q4 2023; a license negotiation right follows, which could validate the SQore platform and create optionality on milestones/economics .
  • Operating discipline: YoY OpEx declines (G&A −19%, R&D −7%) drove improved YoY EPS (−$0.10 vs −$0.20) despite revenue pressure, showcasing cost control in a capital‑efficient model .
  • Liquidity improved sequentially (cash & equivalents to $1.77M from $0.48M) following completion of the $4.1M private placement; current liabilities fell by ~$1.02M vs Q2, improving the near‑term balance sheet profile .
  • IP and CMC readiness advancing: multiple new patents/notices and a manufacturing partnership for a lead excipient support downstream partnering and potential commercialization paths .
  • Revenue cadence likely remains collaboration‑driven near term; Q3 revenue decline was tied to lower hours late in the evaluation phase, underscoring the importance of post‑evaluation outcomes (e.g., licensing) for future top‑line visibility .
  • Governance/compliance remains a watch item: Nasdaq continued listing was conditional (as of Q2), so execution against milestones remains important to avoid listing disruptions .
  • No formal guidance and no transcript this quarter increase information asymmetry; monitoring upcoming 8‑Ks/press releases around the Regeneron evaluation outcome is critical for trading decisions .